Patent ID: 7135550

Claim:
A hybrid ligand represented by the general formula: R1-Y—R2, wherein: (i) R1 represents a first ligand selected from: a steroid, retinoic acid, beta-lactam antibiotic, cannabinoid, nucleic acid, polypeptide, FK506, FK506 derivative, rapamycin, tetracycline, methotrexate, novobiocin, maltose, glutathione, biotin, vitamin D, dexamethasone, estrogen, progesterone, cortisone, testosterone, nickel, 2,4-diaminopteridine or cyclosporin, or a derivative thereof with structural modifications that retain a biological activity thereof; (ii) Y represents a polyethylene linker having the general formula (CH 2 —X—CH 2 ) n , where X represents O, S, SO, or SO 2 , and n is an integer from 2 to 25; and, (iii) R2 represents a user-specified second ligand different from R1 selected from: a peptide, nucleic acid, carbohydrate, polysaccharide, lipid, prostaglandin, acyl halide, alcohol, aldehyde, alkane, alkene, alkyne, alkyl, alkyl halide, alkaloid, amine, aromatic hydrocarbon, sulfonate ester, carboxylate acid, aryl halide, ester, phenol, ether, nitrile, carboxylic acid anhydride, amide, quaternary ammonium salt, imine, enamine, amine oxide, cyanohydrin, organocadmium, aldol, organometallic, aromatic hydrocarbon, nucleoside, or a nucleotide.